| 摘要 |
Disclosed are compounds of Formula I: and the pharmaceutically acceptable salts thereof, wherein "A" is S-; -SO-, -SO2-, -O- or NRa-, and Ra, and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease. |
